Back to Dashboard







Eli Lilly and Company (LLY)
Real-time intraday values
Market Overview
From:
To:
LLY Intraday
No data available
SymbolLLY
IPO DateJun 1, 1972
CEOMr. David A. Ricks
Full Time Employees50k
SectorHealthcare
IndustryDrug Manufacturers - General
CountryUnited States
ExchangeNYSE
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Performance
| Period | Return % | Value Change |
|---|---|---|
| 1 Day | -0.05% | -0.55 US$ |
| 5 Days | +2.19% | +22.80 US$ |
| 1 Month | +20.42% | +180.49 US$ |
| 6 Months | -3.61% | -39.89 US$ |
Analyzing Market with AI
Evaluating the last 30 days of history and fundamental metrics of LLY...
Key Statistics
Market Cap
949.13B
P/E Ratio
37.85
Div Yield
65.00%
52W High
$1133.95
52W Low
$623.78
Analyst Consensus
CONSENSUSBuy
BULLISH2477.4%
NEUTRAL619.4%
BEARISH13.2%
52W Analyst Price Targets
Min Target
$850.00
$850.00
Max Target
$1500.00
$1500.00
Current$1064.45
Avg Target$1211.03
Analyst Recommendations
Precio Objetivo:$1211.03($850.00 - $1500.00)
Community Thoughts
Share your analysis and sentiment on LLY
Join the community to share your analysis
Latest News for LLY
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Zacks•May 26, 2026, 01:00 PM
Here’s What the Street is Saying About Eli Lilly and Company (LLY)
Insider Monkey•May 26, 2026, 12:10 PM
LLY Stock Back In Spotlight After Sealing 10th Acquisition This Year – Expands Beyond Obesity With $3.8B Vaccine Bet
Stocktwits•May 26, 2026, 12:25 PM
Eli Lilly Stock Eyes Best Month This Year As Cholesterol, Obesity Drug Tailwinds Build
Stocktwits•May 26, 2026, 05:08 AM
Eli Lilly to Acquire Curevo, LimmaTech Biologics, Vaccine Company for Up to $3.83 Billion
MT Newswires•May 26, 2026, 11:21 AM
Eli Lilly's Experimental Gene Therapy Lowers Cholesterol in Early-Stage Study
MT Newswires•May 26, 2026, 08:27 AM
4 Large-Cap Pharma Stocks to Buy as Industry Recovery Accelerates
Zacks•May 26, 2026, 12:49 PM
Eli Lilly to Acquire Three Vaccine Developers for Up to $3.83 Billion
MT Newswires•May 26, 2026, 12:57 PM
BofA Securities Raises Eli Lilly Price Target to $1,251 From $1,133
MT Newswires•May 26, 2026, 12:17 PM
Lilly announces three acquisitions to build infectious disease portfolio
PR Newswire•May 26, 2026, 10:45 AM